AC Immune SA ACIU 深 滬

AC Immune Presents New Preliminary Data From Phase 1 Trial Of TDP-43 Positron Emission Tomography Tracer ACI-19626 Showing Increased Uptake In Brains Of Patients With Amyotrophic Lateral Sclerosis

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALSPresentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic

05-22 19:08

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS

AC Immune presented new Phase 1 data showing higher uptake of its TDP-43 PET tracer ACI-19626 in the brains of ALS patients compared to healthy controls. The tracer detected TDP-43 pathology in key brain regions, with previous data also showing its ability to detect TDP-43 in genetic frontotemporal dementia (FTD). ACI-19626 demonstrated good safety, tolerability, and a suitable pharmacokinetic profile for brain imaging. The ongoing Phase 1 trial ...

05-22 11:00

AC Immune CEO Andrea Pfeifer to retire after 23 years

AC Immune (ACIU) on Tuesday said co-founder and CEO Andrea Pfeifer will retire at the company’s upcoming annual general meeting after leading the neurodegenerative disease drug developer for 23 years....

05-12 20:15

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM

AC Immune announced that Dr. Andrea Pfeifer, its co-founder and CEO, will retire at the upcoming AGM after 23 years of service. Dr. Martin Zügel, the Board Chair, will serve as interim CEO while a permanent successor is sought. Dr. Pfeifer will continue as an advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board. The company is well-positioned to create value through its pipeline and partnerships, with a strong finan...

05-12 11:00

美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元

今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元

05-05 11:40

BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

05-04 17:25

AC Immune Q1 EPS $(0.19) Beats $(0.20) Estimate, Sales $1.429M Beat $1.000M Estimate

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 9.52 percent increase over losses of $(0.21) per share from the same

04-30 19:51

AC Immune Announces It Dosed The First Patients In Cohort AD4 In The Ongoing Phase 1b/2 ABATE Trial

As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners' exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of

04-30 19:13

AC Immune Amended Its 2018 Agreement With Eli Lilly For Tau Aggregation Inhibitor Drugs For Alzheimer's And Other Neurodegenerative Diseases, AC Immune Will Receive CHF10M

Under this amendment, AC Immune will receive a CHF10 million upfront payment and a subsequent milestone payment with Phase 1 dosing, in addition to milestones announced in a prior amendment. AC Immune is eligible for

04-07 19:04

AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly

04-07 11:00